Search Results - qingyun+(jim)+liu

3 Results Sort By:
LGR4 Specific Monoclonal Antibodies and Their Use
­Researchers at UTHealth have isolated and characterized monoclonal antibodies as well as antibody fragments that specifically binding to LGR4, a 7TM receptor that is highly expressed in major types of solid tumors, including but not limited to colorectal cancer, non-small cell lung cancer, and ovarian cancer. These LGR4 specific monoclonal antibodies...
Published: 9/22/2022   |   Inventor(s): Qingyun (Jim) Liu
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics, Diagnostics, Research Materials
Mutants and Drug Conjugates of R-Spondin Polypeptides for Cancer Therapy
­R-spondins (RSPOs) are secreted proteins with critical roles in cancer development through binding to LGRs and RNF43/ZNRF3 and potentiating Wnt signaling. Various RSPO mutants were discovered that bind to LGRs but no longer function in Wnt signaling. Fc fusion protein of the RSPO mutants, so called RSPO peptibodies, were conjugated with cytotoxic...
Published: 9/22/2022   |   Inventor(s): Qingyun (Jim) Liu
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Methods and composition for novel anti-cancer treatments
Background: The Wnt signaling pathway plays essential roles in development and is frequently hyperactivated in cancer cells as a driving mechanism. Nearly 90% of colon cancers, for examples are mutated in this pathway. However, direct targeting of this pathway for cancer drug discovery has been challenging due to receptor redundancy and complexity....
Published: 9/22/2022   |   Inventor(s): Qingyun (Jim) Liu
Keywords(s):  
Category(s): Therapeutics, Diagnostics
© 2023. All Rights Reserved. Powered by Inteum